Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766724 | 0.83 | MMP2 (0.35) | MMP2NMT2NMT1GNAI3GNAO1 | |
| SCHEMBL8766736 | 0.83 | MMP2 (0.35) | MMP2NMT2NMT1GNAI3GNAO1 | |
| SCHEMBL8766726 | 0.83 | MMP2 (0.35) | MMP2NMT2NMT1GNAI3GNAO1 | |
| SCHEMBL23168318 | 0.82 | MEN1 (0.42) | MMP2KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL22005704 | 0.82 | MEN1 (0.42) | MMP2KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL20685658 | 0.79 | MMP2 (0.44) | MMP2ALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL20685656 | 0.79 | MMP2 (0.42) | MMP2KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL22162694 | 0.79 | MMP2 (0.42) | MMP2KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL20685654 | 0.79 | MMP2 (0.42) | MMP2KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL20615612 | 0.78 | PAOX (0.48) | MMP2GNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180459-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180459-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | TP53 4304/4885SMN1; SMN2 4875/4885MMP2 820/4885 |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | TP53 4026/4885SMN1; SMN2 4637/4885MMP2 147/4885 |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | TP53 4304/4885SMN1; SMN2 4875/4885MMP2 820/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | TP53 3573/4885SMN1; SMN2 4885/4885MMP2 845/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | TP53 3744/4885SMN1; SMN2 4260/4885MMP2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.